SpaceX Goes on $60 Billion AI Buying Spree

Motley Fool Hidden Gems Investing

The Motley Fool

Investing, Business

4.3 • 3.1K Ratings

🗓️ 22 April 2026

⏱️ 15 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

SpaceX is buying another AI company, this time it’s Cursor. The space company has transformed itself into an AI company, but does this mean it can catch up to Google, Anthropic, or OpenAI? Plus, we cover Amazon’s move into GLP-1s and Meta’s new AI use case. Travis Hoium, Lou Whiteman, and Rachel Warren discuss: - SpaceX agrees to buy Cursor - Amazon gets into GLP-1s - Meta’s AI spyware Companies discussed: Amazon (AMZN), Hims & Hers (HIMS), Meta Platforms (META), Alphabet (GOOG, GOOGL). Host: Travis Hoium Guests: Lou Whiteman, Rachel Warren Engineer: Dan Boyd, Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	SpaceX is making another big acquisition this time buying cursor.
0:09.8	Does that make sense long term?
0:12.1	Motley Full Money starts now.
0:20.7	Welcome back to Motley Full Money.
0:22.6	Amazon announced this week that it's getting into the GLP1 game.
0:26.5	The company is bringing GLP1 pills and pens, as they're now known to its platform.
0:32.9	This doesn't necessarily include the prescriptions.
0:35.9	You can just get your access to GLP1s.
0:37.8	You can also go through the Amazon prescriptions.
0:40.8	But, you know, Rachel, this is interesting because Amazon keeps moving more and more into the medical field.
0:46.8	You can get more and more of your prescriptions there.
0:49.4	Who are they, what's the goal here and who are they ultimately going after?
0:53.8	Yeah, this is a really interesting bit of news.
0:57.0	I mean, it's a major shift.
0:58.8	I think one of the things that Amazon is looking to solve here is to fix one of the messier
1:03.4	parts of healthcare, which is getting the actual medication to consumers.
1:07.2	And Amazon's really leading into their strength as a logistics and pharmacy powerhouse.
1:16.6	So under this new program, if you have an existing prescription for a GLP1 medication, or you go and visit a doctor through one medical, either virtually or in person, you can get a
1:21.6	prescription for a GLP1, and Amazon is going to help facilitate that process of getting it to you as the consumer.
1:28.7	You know, bringing GLP1 pills and pens directly into the Amazon pharmacy ecosystem,
1:34.1	they're really cutting out the middlemen.
1:35.8	They're focusing on the supply chains.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.